ROBIN HAYES: Open Payments
NPI 1164043899 · SAINT LOUIS, MO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$919 in 51 payments from 11 companies in 2025. Trend: 2023 $689 · 2024 $140 · 2025 $919
Food & beverage: $919
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 32 | $449 |
| Eisai Inc. | 4 | $84 |
| Axsome Therapeutics, Inc. | 3 | $84 |
| Amneal Pharmaceuticals LLC | 3 | $70 |
| Neurocrine BioSciences, Inc. | 2 | $58 |
| PFIZER INC. | 2 | $38 |
| Lundbeck LLC | 1 | $33 |
| Novartis Pharmaceuticals Corporation | 1 | $30 |
| Merz Pharmaceuticals, LLC | 1 | $27 |
| Otsuka America Pharmaceutical, Inc. | 1 | $26 |
Products named: UBRELVY, QULIPTA, Leqembi, Symbravo, CREXONT, INGREZZA, BOTOX, NURTEC ODT.
Industry payments across MO — which companies pay providers there.
